dupilumab
sanofi,regeneron
['dupilumab', 'dupixent']
dupixent (dupilumab) late-breaking data at aad show - globenewswire symptoms were assessed every one or two weeks during the trial. ... asthma, crswnp, eoe or prurigo nodularis, in different age populations.
#TheAsthmaCures https://t.co/vRkYeArZWg helping those with chronic #asthma https://t.co/7SMiyxzFdG resolving https://t.co/nIlzNga34W https://t.co/T67YXQ3eBZ